Researchers design 'prodrug' that targets cancer cells' big appetite for glutamine, leaving healthy cells unharmed
by Johns Hopkins University School of MedicineSchematic showing DRP-104's bio-activation to DON in tumor and bio-inactivation to an inert metabolite in GI tissues. Credit: Jennifer E. Fairman
Updated on: February 18,2024
14

Researchers design 'prodrug' that targets cancer cells' big appetite for glutamine, leaving healthy cells unharmed
by Johns Hopkins University School of MedicineSchematic showing DRP-104's bio-activation to DON in tumor and bio-inactivation to an inert metabolite in GI tissues. Credit: Jennifer E. Fairman
Updated on:February 18,2024
14
